基于基因诊断的鞍旁高分化软骨肉瘤一例并文献复习
Highly Differentiated Chondrosarcoma in the Parasellar Region Based on Genetic Diagnosis: A Case Report and Literature Review
DOI: 10.12677/acm.2024.1461824, PDF,   
作者: 崔海瑞, 李志键, 张向荣, 孙国柱, 于宝海, 杨建凯*:河北医科大学第二医院神经外科,河北 石家庄
关键词: 软骨肉瘤颅底基因诊断显微外科手术预后Chondrosarcoma Skull Base Gene Diagnosis Microsurgery Prognosis
摘要: 目的:报道鞍旁软骨肉瘤的临床特点,探讨本病的特征性影像学表现及基因检测在其临床诊治中的价值。方法:回顾1例鞍旁高分化软骨肉瘤患者的临床资料并复习相关文献。结果:本例报道的鞍旁高分化软骨肉瘤患者以头痛为主要表现,MRI检查示右侧蝶鞍部团块状异常信号,神经导航下手术分块全切肿瘤,术后行病理组织免疫组化及基因检测。患者术后恢复良好,随访6个月无复发。结论:对于病理特征不明显的软骨肉瘤,标本的基因检测非常重要,往往可以发现明确的基因突变或融合。诊疗过程中需加强对其的认识,及时给予治疗。
Abstract: Objective: To report the clinical characteristics of parasellar chondrosarcoma and explore the characteristic imaging manifestations and genetic testing value in its clinical diagnosis and treatment. Method: Review the clinical data of a patient with highly differentiated chondrosarcoma of the parasellar region and review relevant literature. Result: The patient with highly differentiated chondrosarcoma of the sella turcica reported in this case presented with headache as the main manifestation. MRI examination showed abnormal signals in the right sella turcica, and the tumor was surgically excised in blocks under neuronavigation. Pathological tissue immunohistochemistry and genetic testing were performed postoperatively. The patient recovered well after surgery and was followed up for 6 months without recurrence. Conclusion: For chondrosarcoma with unclear pathological features, genetic testing of the specimen is very important, often revealing clear gene mutations or fusion. During the diagnosis and treatment process, it is necessary to strengthen the understanding of it and provide timely treatment.
文章引用:崔海瑞, 李志键, 张向荣, 孙国柱, 于宝海, 杨建凯. 基于基因诊断的鞍旁高分化软骨肉瘤一例并文献复习[J]. 临床医学进展, 2024, 14(6): 666-670. https://doi.org/10.12677/acm.2024.1461824

参考文献

[1] Awad, M., Gogos, A.J. and Kaye, A.H. (2016) Skull Base Chondrosarcoma. Journal of Clinical Neuroscience, 24, 1-5. [Google Scholar] [CrossRef] [PubMed]
[2] 赵静静, 张志红, 甄俊平. 异柠檬酸脱氢酶基因突变在软骨肉瘤中的研究进展及展望[J]. 中国全科医学, 2024, 27(11): 1400-1404.
[3] 阎晓玲. 软骨肉瘤[J]. 中国现代神经疾病杂志, 2019, 19(10): 765.
[4] 陈绪清, 廖华, 汪雷, 等. 中颅窝底罕发肿瘤3例临床分析[J]. 武汉大学学报(医学版), 2021, 42(2): 317-321.
[5] Liu, H., Li, Z., Xue, Y., et al. (2023) A Multicenter Retrospective Analysis of Clinical Outcomes of Intracranial Chondrosarcoma in 26 Patients. Scientific Reports, 13, Article No. 14647. [Google Scholar] [CrossRef] [PubMed]
[6] Uneda, A., Kurozumi, K., Fujimura, A., et al. (2020) Intracranial Mesenchymal Chondrosarcoma Lacking the Typical Histopathological Features Diagnosed by HEY1-NCOA2 Gene Fusion. NMC Case Report Journal, 7, 47-52. [Google Scholar] [CrossRef] [PubMed]
[7] Molenaar, R.J., Coelen, R.J.S., Khurshed, M., et al. (2017) Study Protocol of a Phase IB/II Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated or IDH2-Mutated Solid Tumours. BMJ Open, 7, e014961. [Google Scholar] [CrossRef] [PubMed]
[8] 冯潇, 叶胜兵, 戴程婷, 等. 鞍区原发性软骨肉瘤5例临床病理学观察[J]. 临床与实验病理学杂志, 2023, 39(10): 1182-1186.
[9] 周良辅. 脑膜瘤的精准医学现状[J]. 中华脑科疾病与康复杂志(电子版), 2021, 11(4): 193-195.
[10] Palmisciano, P., Haider, A.S., Sabahi, M., et al. (2021) Primary Skull Base Chondrosarcomas: A Systematic Review. Cancers, 13, Article 5960. [Google Scholar] [CrossRef] [PubMed]
[11] 李竟源, 许凯, 刘时璋, 等. 人软骨肉瘤中miR-140-5p靶基因预测验证及对靶基因表达的调控作用观察[J]. 山东医药, 2019, 59(6): 13-16.
[12] Tang, D.M., Cutri, R.M., Wu, A.W., et al. (2023) Proton Therapy for Skull Base Chondrosarcoma. Journal of Neurological Surgery Reports, 84, e144-e145. [Google Scholar] [CrossRef] [PubMed]
[13] 杨凤东, 王一明, 贾鑫, 等. 颅内软骨肉瘤的临床特征和预后: 附12例报告[J]. 中华神经外科杂志, 2022, 38(9): 900-905.